

Accepted Manuscript

Regulation of Ectodomain Shedding of ADAM33 *In Vitro* and *In Vivo*

Elizabeth R. Davies, PhD, Laura Denney, PhD, Marieke Wandel, MSc, Clare M. Lloyd, PhD, Donna E. Davies, PhD, Hans Michael Haitchi, MD, PhD



PII: S0091-6749(19)30183-6

DOI: <https://doi.org/10.1016/j.jaci.2019.01.026>

Reference: YMAI 13869

To appear in: *Journal of Allergy and Clinical Immunology*

Received Date: 18 September 2018

Revised Date: 10 January 2019

Accepted Date: 23 January 2019

Please cite this article as: Davies ER, Denney L, Wandel M, Lloyd CM, Davies DE, Haitchi HM, Regulation of Ectodomain Shedding of ADAM33 *In Vitro* and *In Vivo*, *Journal of Allergy and Clinical Immunology* (2019), doi: <https://doi.org/10.1016/j.jaci.2019.01.026>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Regulation of Ectodomain Shedding of ADAM33 *In Vitro* and *In Vivo*

Elizabeth R. Davies PhD^{1*}, Laura Denney PhD², Marieke Wandel MSc¹, Clare M. Lloyd PhD², Donna E. Davies PhD^{1,3,4}, Hans Michael Haitchi MD, PhD^{1,3,4}

¹ Brooke Laboratories, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, UK

² Inflammation, Repair & Development, National Heart and Lung Institute, Imperial College London, London, UK

³ National Institute for Health Research (NIHR) Southampton Biomedical Research Centre at University Hospital Southampton NHS Foundation Trust, UK

⁴ Institute for Life Sciences, University of Southampton, Southampton, UK

* Corresponding Author: Elizabeth R. Davies

Address: Brooke Laboratories, Mail Point 888, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Tremona Road, Southampton, Hampshire, SO16 6YD, UK

Tel: +44 23 8120 6736, Fax: +44 23 8051 1761

Email: E.Davies@soton.ac.uk

Conflict of Interest Statement

The authors declare the following conflicts of interest:

DED reports personal fees from Synairgen, which is outside the submitted work. All other authors have nothing to declare.

Funding: This work was supported by a Medical Research Council UK Clinician Scientist Fellowship to HMH (G0802804), a grant from the Asthma, Allergy & Inflammation (AAIR) Charity to ERD & HMH, a Medical Research Foundation/Asthma UK grant to HMH and DED (MRFAUK-2015-322) and a Wellcome Trust Senior Fellowship to CML (CML & LD; 087618/Z/08/Z).

Capsule summary: TGF- β signaling regulates ectodomain shedding of ADAM33 mainly via an autocatalytic mechanism and is essential for shedding of catalytically-active ADAM33 *in vivo*. These mechanisms have implications for the genetic contribution of ADAM33 to asthma and BHR.

Key words: ADAM33, TGF- β , ectodomain shedding, asthma, allergy

Abbreviations: ADAM33: a disintegrin and metalloprotease 33; BALF: bronchoalveolar lavage fluid; HDM: house dust mite; IL-33: interleukin-33; TGF- β : transforming growth factor beta

To the Editor:

A disintegrin and metalloprotease (ADAM)33 is a susceptibility gene for asthma and bronchial hyperresponsiveness (BHR). ADAM33 is a transmembrane protein but a soluble protein containing the metalloprotease domain (sADAM33) has previously been identified in bronchoalveolar lavage fluid (BALF) from asthmatic subjects and its levels significantly and negatively correlated with FEV₁, suggesting a role in the development of airflow obstruction (1). We have shown that sADAM33 in asthmatic BALF is enzymatically active and that the sADAM33 metalloprotease causes angiogenesis and myogenesis *in vivo* or *ex vivo* (2, 3). Furthermore, *in vivo* allergen challenge causes shedding of enzymatically-active sADAM33 into BALF of wildtype mice, and in a transgenic mouse model, lung-specific sADAM33 expression causes airway remodeling which enhances eosinophil recruitment with associated BHR following allergen sensitization and challenge (2). Although transforming growth factor beta (TGF- β) is a trigger for sADAM33 release *in vitro* (3), there is no mechanistic information or evidence of *in vivo* relevance. Here we sought to characterize the mechanism(s) of TGF- β -induced ectodomain shedding of murine ADAM33 and to determine its importance for shedding of ADAM33 *in vivo*. As it is not possible to test directly the importance of TGF- β in ectodomain shedding in human asthma, we characterized the mechanism(s) of the TGF- β induced ectodomain shedding of murine ADAM33 and determined its importance for shedding of ADAM33 *in vivo*. Detailed methodology is provided in the Methods section in this article's Online Repository at www.jacionline.org.

Initially, we confirmed that murine ADAM33 was similar to human ADAM33 in its sensitivity to TGF- β induced ectodomain shedding (3). As expected, TGF- β treatment caused a dose-dependent increase in sADAM33 in supernatants of Cos-7 cells expressing murine ADAM33 (Fig E1A, B). The main band had a molecular weight around 102kDa, indicating

that the entire ectodomain had been shed; however further processing was also evident suggesting loss of the inhibitory pro-domain. Consistent with this, there was a significant increase in ADAM33 enzymatic activity in cell-free supernatants following TGF- β treatment (Fig E1C). Pericellular proteolysis is frequently mediated by members of the ADAM or MT-MMP families that are sensitive to the broad-spectrum hydroxamic acid based inhibitor, GM6001; however we found it did not affect the shedding (Fig E2A,B) or activity (Fig E2C) of ADAM33. We also confirmed that GM6001 also had no effect on the activity of purified recombinant ADAM33 (Fig E2D). As ADAM33 has a unique substrate-binding site and its catalytic activity is insensitive to GM6001 (4), we postulated that ADAM33 ectodomain shedding was autocatalytic. Consistent with this, mutation of E347A in the catalytic site suppressed shedding of sADAM33 both at baseline and in response to TGF- β (Fig 1A) and this was accompanied by a significant reduction in enzymatic activity in cell free supernatants (Fig 1B). These data suggest that a substantial component of the shedding of sADAM33 is autocatalytic.

TGF- β activates multiple signals including SMAD and non-SMAD pathways. Inhibition of SMAD signaling using SB341452, significantly suppressed TGF- β_1 induced shedding of immunoreactive and enzymatically active ADAM33 (Fig 1C,D). In contrast, the MAP2K/MEK inhibitor, PD98059 dose-dependently increased shedding of immunoreactive and enzymatically active forms of sADAM33 (Fig 1E,F). These data suggest a complex effect of TGF- β signaling with SMAD activation being stimulatory for ADAM33 shedding, whereas MAPK activation has a negative regulatory effect. The latter effect may be mediated via TIMP-3, a known inhibitor of ADAM33 enzymatic activity (5), which is reported to be induced by TGF- β via MAPK signaling (6). Thus, inhibiting MAPK activation with PD98059 may inhibit TIMP3 expression and release ADAM33 from the effects of this

natural inhibitor leading to increased autocatalytic shedding and augmented enzyme activity. While ectodomain shedding can be regulated by natural protein inhibitors, other mechanisms including membrane trafficking, protein maturation and substrate presentation have also been shown to be important for the regulation of other sheddases (7). Whether release of ADAM33 is preceded by its membrane trafficking or maturation and/or by assembly into higher order complexes requiring additional protein interactions to exosites located either on the ADAM33 or adapter proteins remains to be determined.

Epithelial injury leads to release of TGF- β and we have postulated that this is the source of the TGF- β that drives the increase in sADAM33 which is observed in response to allergen challenge *in vivo* (2). To test this hypothesis, we utilized BALF from mice in which lung epithelial *Tgfb1* was conditionally deleted in bronchial epithelial club cells before intra-nasal administration of either 25 μ g HDM extract or recombinant murine IL-33 (8). After HDM challenge, lower levels of sADAM33 could be detected in the BALF of *Tgfb1*^{-/-} mice compared to littermate controls (Fig 2A) and it also contained less sADAM33 enzymatic activity (Fig 2B). In the same way, when mice were challenged with IL-33, BALF from *Tgfb1*^{-/-} mice had a lower level of sADAM33 immunoreactive protein (Fig 2C) and enzymatic activity (Fig 2D). Of note, exogenous TGF- β alone was ineffective at stimulating shedding of ADAM33 *in vivo*. This might be explained either by the fact that TGF- β could not pass through the intact epithelium of unchallenged mice and/or by the low dose and short half-life of the growth factor which did not allow sufficient time for it to pass through the epithelium to reach the subepithelial mesenchymal cells where ADAM33 is expressed (9).

Epithelial-derived IL-33 induces rapid release of TGF- β into the airways to enhance migration of ILCs and development of a robust ILC2 response that initiates allergic immunity

(9). Since we found that epithelial-derived TGF- β is also required for ectodomain shedding of ADAM33, it may be speculated that sADAM33 can contribute to the recruitment or activation of ILCs or other innate immune cells, either by affecting matrix turnover or by promoting growth factor or chemokine shedding. Of note, polymorphisms in *TGFB*, *IL33* and *ADAM33* genes have each been associated with asthma susceptibility, yet each has a small overall effect on disease development. The involvement of three susceptibility gene products in epithelial responses to allergens highlights how they may co-operate to amplify the downstream asthmatic responses.

Identification of the involvement of TGF- β in ectodomain shedding of ADAM33 in an *in vivo* model strengthens the case for exploring how human polymorphic variation in the *ADAM33* gene is linked to asthma pathogenesis. Four SNPs (S1, S2, T1, and T2) encode amino acid substitutions in the transmembrane and cytoplasmic domain of ADAM33 and have been associated with asthma (4). Although the intracellular domain of ADAM33 is relatively short, it is very rich in prolines, having a putative SH3 binding site where the T2 SNP is located, a casein kinase I/II phosphorylation site and a MAPK consensus sequence which is likely to be important for regulation of ADAM33 function, especially as we have identified a negative regulatory role for MAPK in our current studies. Further work is required to determine whether this effect is direct and involves ADAM33 phosphorylation or indirect via inhibitors such as TIMP3. Alternatively, one mutation Ala395Val is located within the catalytic domain (4), which may directly affect catalytic activity.

In summary, we have provided direct evidence that epithelial-derived TGF- β is an important regulator of ectodomain shedding of enzymatically active ADAM33 from the mesenchyme. This process appears largely to be autocatalytic and involves SMAD signaling, but is

negatively regulated by MAPK signaling. These findings highlight the importance of epithelial-mesenchymal cross talk in asthma pathogenesis and underscore the potential for co-operation between different asthma susceptibility genes to drive disease pathogenesis.

Elizabeth R. Davies, PhD¹

Laura Denney, PhD²

Marieke Wandel, MSc¹

Clare M. Lloyd, PhD²

Donna E. Davies, PhD^{1,3,4}

Hans Michael Haitchi, MD, PhD^{1,3,4}

¹ Brooke Laboratories, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, UK

² Inflammation, Repair & Development, National Heart and Lung Institute, Imperial College London, London, UK

³ National Institute for Health Research (NIHR) Southampton Biomedical Research Centre at University Hospital Southampton NHS Foundation Trust, UK

⁴ Institute for Life Sciences, University of Southampton, Southampton, UK

References

1. Lee JY, Park SW, Chang HK, Kim HY, Rhim T, Lee JH, et al. A disintegrin and metalloproteinase 33 protein in patients with asthma: Relevance to airflow limitation. *Am J Respir Crit Care Med*. 2006;173(7):729-35.
2. Davies ER, Kelly JF, Howarth PH, Wilson DI, Holgate ST, Davies DE, et al. Soluble ADAM33 initiates airway remodeling to promote susceptibility for allergic asthma in early life. *JCI Insight*. 2016;1(11).
3. Puxeddu I, Pang YY, Harvey A, Haitchi HM, Nicholas B, Yoshisue H, et al. The soluble form of a disintegrin and metalloprotease 33 promotes angiogenesis: implications for airway remodeling in asthma. *J Allergy Clin Immunol*. 2008;121(6):1400-6, 6.e1-4.
4. Orth P, Reichert P, Wang W, Prosise WW, Yarosh-Tomaine T, Hammond G, et al. Crystal structure of the catalytic domain of human ADAM33. *Journal of molecular biology*. 2004;335(1):129-37.
5. Zou J, Zhu F, Liu J, Wang W, Zhang R, Garlisi CG, et al. Catalytic activity of human ADAM33. *J Biol Chem*. 2004;279(11):9818-30.
6. Qureshi HY, Sylvester J, El Mabrouk M, Zafarullah M. TGF-beta-induced expression of tissue inhibitor of metalloproteinases-3 gene in chondrocytes is mediated by extracellular signal-regulated kinase pathway and Sp1 transcription factor. *J Cell Physiol*. 2005;203(2):345-52.
7. Lichtenthaler SF, Lemberg MK, Fluhrer R. Proteolytic ectodomain shedding of membrane proteins in mammals-hardware, concepts, and recent developments. *EMBO J*. 2018;37(15).
8. Denney L, Byrne AJ, Shea TJ, Buckley JS, Pease JE, Herledan GM, et al. Pulmonary Epithelial Cell-Derived Cytokine TGF-beta1 Is a Critical Cofactor for Enhanced Innate Lymphoid Cell Function. *Immunity*. 2015;43(5):945-58.
9. Haitchi HM, Powell RM, Shaw TJ, Howarth PH, Wilson SJ, Wilson DI, et al. ADAM33 expression in asthmatic airways and human embryonic lungs. *Am J Respir Crit Care Med*. 2005;171(9):958-65.

Figure Legends

FIGURE 1: Regulation of ADAM33 shedding. Cos-7 cells expressing full length catalytically active murine ADAM33 (A-F) or inactive ADAM33 E347A (A,B) were treated without or with TGF- β (5ng/ml) for 8hr and SMAD (SB431542) (C,D) or MAPK (PD98059) (E,F) inhibitors, as indicated. Soluble ADAM33 immunoreactivity and enzymatic activity in cell-free supernatants were assessed by Western blotting (inset) with densitometry (arbitrary units, AU) (A,C,E) or in a Fluorescence Resonance Energy Transfer (FRET) peptide cleavage assay, respectively; in panel B, enzymatic activity in the supernatants is expressed as a percent of that measured in supernatants from untreated cells expressing full length active ADAM33 while in panels D and F, activity is expressed as a percent of that measured in supernatants from TGF- β -treated cells. Data are expressed as mean + SD (n=4 independent experiments). # p<0.05, ## p<0.01 vs control, *p<0.05, **p<0.01, ***p<0.001

FIGURE 2: Epithelial TGF- β enhances shedding of ADAM33 *in vivo*. Epithelial (Epi)*Tgfb*^{-/-} or littermate *Tgfb*^{+/+} control mice were challenged with intranasal house dust mite (HDM) extract (A,B) or recombinant IL-33 (C,D) and, where indicated, recombinant TGF- β (C,D). Soluble ADAM33 immunoreactivity and enzyme activity in bronchoalveolar lavage fluid (BALF) were assessed by Western blotting (A,C) or FRET peptide cleavage assay, respectively; enzyme activity is expressed as relative fluorescent units per minute (RFU/min) (B,D). Data are mean + SD (n= 4–6 mice per group). Data are representative of 2 independent experiments. ## p<0.01, ### p<0.001 vs control, *p<0.05, ***p<0.001




Figure 1







Figure 2






Figure E1







Figure E2

Online Repository

Methods

Cell culture

The Cos-7 cell line, a fibroblast-like cell line were grown in Dulbecco's Modified Eagles Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 50 units/ml penicillin, 50µg/ml streptomycin, 2mM L-glutamine, 1mM sodium pyruvate and 1x non-essential amino acids (DMEM/FBS) (all from Life Technologies, Paisley, UK). For transfection, cells were placed in non-supplemented Opti-MEM (Life Technologies).

Transfection of full-length mouse ADAM33

Cos-7 cells were transfected with a plasmid encoding full-length murine ADAM33 (MR217277 clone, NM_033615; OriGene, MD, USA) or green fluorescence protein (GFP) using X-treme Gene 9 reagent (Roche, Southampton, UK). After 24h, cells were treated with TGF- β_1 (Peprotech, London, UK) for 8h to assess ectodomain shedding of ADAM33. The TGF- β_1 isoform was chosen, as this is the major isoform in adult mice (1). Where indicated, cells were pre-incubated for 1h with the ALK5/SMAD inhibitor SB431542 (10µM; Stratech, Ely, UK), the mitogen-activated protein kinase kinase (MAP2K, MEK) inhibitor PD98059 (10 or 25µM, Sigma, Poole UK), the broad-spectrum metalloprotease inhibitor GM6001 (10µM; Merck, Millipore, Watford, UK) or vehicle control before addition of 5ng/ml TGF- β_1 . Cell-free supernatants were harvested and cells were lysed into RIPA buffer.

ADAM33 pull down with concanavalin A beads

Concanavalin A-Sepharose 4B beads (ConA) (Sigma) were used to pull down glycosylated ADAM33 from the supernatants of the transfected Cos-7 cells, as previously described (2). In brief, 1ml supernatant was adjusted to contain 20mM Tris HCl pH 7.4, 0.5M NaCl, and

protease inhibitors (Sigma) before addition of activated ConA beads (20 μ l beads per ml sample). After binding overnight at 4°C, the beads were washed twice in 20mM Tris HCl pH 7.4 containing 0.5M NaCl and then twice in 20mM Tris HCl pH 7.4 to remove excess salt. The bound protein was then solubilized into SDS sample buffer containing 0.5M methyl α -D-mannopyranoside for SDS-PAGE and Western blotting.

Fluorescence resonance energy transfer (FRET) peptide cleavage assay

An ADAM33 enzymatic assay was performed using a FRET peptide cleavage assay as previously described (3). All assay measurements were made at 37°C in real time using a Bio-Rad CFX96 machine with a 490-nm (6-carboxyfluorescein; FAM) filter, allowing determination of initial rates. Each reaction contained 7 μ l neat BALF or cell supernatant mixed with 2 μ l 5x-assay buffer (100mM HEPES pH 7, 2.5M NaCl, 50mM CaCl₂ and 1mg/ml bovine serum albumin); the assay was initiated by addition of 44 pmol FRET peptide (DABCYL-YRVAFQKLAE(FAM)K-NH₂) (Severn Biotech, Kidderminster, UK) and 100 pmol ZnCl₂ to make a final reaction volume of 10 μ l. Enzymatic activity was determined by plotting relative fluorescence units (RFU) against time after the background had been subtracted. The rate of the reaction (RFU/min) was determined from the line of best fit in the linear phase of the assay. Control assays utilized human recombinant soluble active ADAM33 (positive control) and mutant ADAM33 (E365A) (negative control) as previously described (2).

SDS-PAGE and western blotting

Solubilized samples from ConA pull down or murine BALF were run on 12.5% acrylamide or 8-20% gradient gels (BioRad, Watford, UK) and transferred onto PVDF membranes. The transferred protein was assessed by Ponceau staining to confirm equivalent protein loading

prior to blocking using 2.5% BSA in TBS/Tween and Western blotting. Membranes were probed with a polyclonal goat antibody against the ectodomain of mouse ADAM33 (AF2434, 1:1000, R&D Systems). Secondary antibody was rabbit anti-goat IgG HRP antibody (Merck; 1:5000). The blots were visualized using enhanced chemiluminescence (Clarity ECL; BioRad) with an Amersham Imager 600 (GE Healthcare, Buckinghamshire, UK); densitometric images were semi-quantified using ImageJ software and data plotted as relative intensity.

The conditional lung epithelial *Tgfb1*^{-/-} mouse model

Mice conditionally lacking lung epithelial *Tgfb* expression (*Ccsp-creTgfb1*^{-/-}) were generated as previously described (4). Mice were pre-treated with doxycycline (DOX) (Sigma) (or vehicle as control) to delete *Tgfb1* from the bronchiolar epithelial cells 72h prior to intra-nasal administration of either 25µg HDM extract (1mg/ml protein solution dissolved in PBS) or 25µl of PBS 5 times a week for 3 weeks. Mice were culled 4h after the final challenge. In other experiments, carrier-free recombinant murine IL-33 (1µg/dose in 25µl PBS) (eBioscience, Thermo Fisher Scientific, Hemel Hempstead, UK) was administered 3 times a week for 1 week and mice culled 18h after the final dose. Where required, 50ng recombinant TGF-β₁ in PBS (R&D Systems) was administered intra-nasally without or with IL-33. At the point of killing, BALF was collected by washing the airways three times with 400µl PBS. After centrifugation to remove cells, supernatants were stored at -80°C. The protein content of the BALF was quantified (BCA Assay, Thermofisher) and normalized before use in ADAM33 enzyme assays or solubilization in 2x Laemmli sample buffer (BioRad) for analysis of sADAM33 protein by Western blotting. Mice of both sexes were used between 7 and 12 weeks of age, housed in specific-pathogen-free conditions, and given food and water *ad libitum*. All procedures were conducted in accordance with the Animals (Scientific Procedures) Act 1986.

Statistics

Normal distribution of the numeric data was evaluated, and appropriate parametric or non-parametric statistical tests applied. All data are parametric and plotted as mean with one standard deviation (SD). Statistical significance was assessed by using Students t-test (unpaired data) with Welch's correction if SDs were not equal for comparisons between 2 groups. For comparison of 3 or more groups a one-way ANOVA with Dunn's multiple comparison test was used. For comparison of 2 or more groups with 2 independent variables, a two-way ANOVA with Tukey's multiple comparison test was used, * = $p < 0.05$, ** = $p < 0.01$, *** = $p < 0.001$

References

1. Pelton RW, Johnson MD, Perkett EA, Gold LI, Moses HL. Expression of transforming growth factor-beta 1, -beta 2, and -beta 3 mRNA and protein in the murine lung. *Am J Respir Cell Mol Biol.* 1991;5(6):522-30.
2. Puxeddu I, Pang YY, Harvey A, Haitchi HM, Nicholas B, Yoshisue H, et al. The soluble form of a disintegrin and metalloprotease 33 promotes angiogenesis: implications for airway remodeling in asthma. *J Allergy Clin Immunol.* 2008;121(6):1400-6, 6.e1-4.
3. Zou J, Zhang R, Zhu F, Liu J, Madison V, Umland SP. ADAM33 enzyme properties and substrate specificity. *Biochemistry.* 2005;44(11):4247-56.
4. Denney L, Byrne AJ, Shea TJ, Buckley JS, Pease JE, Herledan GM, et al. Pulmonary Epithelial Cell-Derived Cytokine TGF-beta1 Is a Critical Cofactor for Enhanced Innate Lymphoid Cell Function. *Immunity.* 2015;43(5):945-58.

Figure Legends

FIGURE E1: TGF- β enhances shedding of murine ADAM33. Cos-7 cells transiently transfected with full length murine ADAM33 or green fluorescent protein (GFP) as control were treated with TGF- β as indicated. Soluble ADAM33 immunoreactivity and enzyme activity in cell-free supernatants were assessed by Western blotting (A) with densitometry (arbitrary units, AU) (B) or FRET peptide cleavage assay, respectively; enzyme activity is expressed as percent of activity found in supernatants from control untreated cells (C). Data are mean + SD and are representative of 4 independent experiments. **p<0.01 ***p<0.001

FIGURE E2: The broad spectrum MMP inhibitor GM6001 does not inhibit ADAM33 shedding. Cos-7 cells transiently transfected with full length murine ADAM33 were pre-incubated with GM6001 (0-10 μ M) for 1h before addition of 5ng/ml TGF- β for 8h. Cell-free supernatants were assessed for soluble ADAM33 by Western blotting (A) with densitometry (arbitrary units, AU) (B) and by FRET peptide cleavage assay (C). Purified recombinant ADAM33 protein was incubated with GM6001 and tested for activity in a FRET peptide cleavage assay (D). Activity is presented as a percent of that measured in the absence of GM6001. Data are expressed as mean + SD and are representative of 4 independent experiments.